Breast Cancer

P=N/A, N=90, Recruiting, Vejle Hospital | Not yet recruiting --> Recruiting

P=N/A, N=388, Recruiting, University Health Network, Toronto | Trial completion date: Aug 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> Jun 2026

P=N/A, N=240, Recruiting, Istituti Clinici Scientifici Maugeri SpA

P=N/A, N=50, Recruiting, University of Pittsburgh

P=N/A, N=600, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed

P=N/A, N=100, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Aug 2025 --> Dec 2025

P=N/A, N=450, Not yet recruiting, Institut Curie | Trial completion date: Dec 2028 --> Aug 2031 | Trial primary completion date: Dec 2026 --> Aug 2031

Furthermore, CD24 scFv-EVs promote the polarization of tumor-infiltrated macrophages toward an M1-like phenotype. These results highlight CD24 blockade as a novel therapeutic strategy to target ovarian and breast cancer cells and enhance macrophage-driven tumor cell clearance.

18F-FDG PET-CT before and after the first cycle of neoadjuvant treatment does not appear to be an effective tool to predict pCR in patients with HER2+ BC.

This trial has been approved by the Institutional Review Board (IRB) and began patient enrollment in January 2024. The trial will provide insights into the safety and effectiveness of a novel combinatorial therapy for BCBM.

Pathway enrichment linked these deregulated miRNAs to key oncogenic networks, particularly PI3K/AKT/mTOR, Wnt/β-catenin, and EMT regulation, demonstrating conserved molecular mechanisms shared with human BC and highlighting their potential as biomarkers in CMTs. These findings provide insights into the molecular mechanisms of CMT adenocarcinoma and suggest the potential of miRNA-based biomarkers for the diagnosis and treatment of CMTs.

Pattern-driven genomic features, including mutational signatures2, homologous recombination deficiency3, tumour mutational burden and tumour heterogeneity scores4, were associated with clinical outcomes, highlighting their potential utility as predictive biomarkers for clinical evaluation of treatments such as CDK4/6 and HER2 inhibitors, as well as adjuvant and neoadjuvant chemotherapy. These findings highlight the power of large-scale, clinically annotated whole-genome sequencing in advancing our understanding of how genomic alterations shape patient outcomes.